SCHEMBL5835510

SCHEMBL5835510

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1ccc(C(F)(F)F)c(O[C@@H]2CCN(C)C2)c1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 17/20 0.62
FPR2 P25090 3/20 0.42
PROKR1 Q8TCW9 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835516 1.00 UTS2R (0.62) UTS2RFPR2PROKR1
SCHEMBL5835439 0.94 UTS2R (0.66) UTS2RFPR2PROKR1
SCHEMBL5835448 0.94 UTS2R (0.66) UTS2RFPR2PROKR1
SCHEMBL5835275 0.89 UTS2R (0.62) UTS2RFPR2PROKR1
SCHEMBL5835278 0.89 UTS2R (0.62) UTS2RFPR2PROKR1
SCHEMBL5835445 0.88 UTS2R (0.65) UTS2RFPR2PROKR1
SCHEMBL5835135 0.87 UTS2R (0.68) UTS2R
SCHEMBL5835130 0.87 UTS2R (0.68) UTS2R
SCHEMBL5835418 0.86 UTS2R (0.69) UTS2RFPR2PROKR1
SCHEMBL5835410 0.86 UTS2R (0.69) UTS2RFPR2PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP claimed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885FPR2 203/4885PROKR1 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.